BSECompany Update4d ago · 5 Nov 2026, 09:21 pm

Please find the enclosed intimation of the Company as per the captioned subject for your reference.

AstraZeneca Pharma India Ltd · 506820

✦ AI SummaryRegulatory

AstraZeneca Pharma India Ltd has informed about a potential revised demand notice from the Bengaluru North City Corporation or Greater Bengaluru Authority, requiring improvement charges and interest under the Greater Bengaluru Governance Act, 2024. The Company has made an additional provision of INR 156.1 million in its books of accounts, based on estimates.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk3/10
Liquidity Impact6/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

AstraZeneca Pharma India Ltd - 506820 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Update

Attachments (1)

📄

e356c36e-0b89-4676-8827-8c00b3cacf19.pdf

pdf

Download →
View document text
November 5, 2026 The Manager- Listing BSE Limited P J Towers, Dalal Street, Fort, Mumbai – 400 001 The Manager- Listing National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex, Bandra (E), Mumbai – 400 051 Dear Sir/Madam, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Update Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in furtherance to our earlier intimation dated January 21, 2025, we hereby inform that the Company may likely receive a revised demand notice from the Bengaluru North City Corporation or Greater Bengaluru Authority (successor to Bruhat Bengaluru Mahanagara Palike), requiring improvement charges and applicable interest thereon under the provisions of Greater Bengaluru Governance Act, 2024 read with Karnataka Municipal Corporations Act, 1976. In this regard, please find the details as required under the SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 attached herewith as Annexure – A. Kindly take the above information on record. Thanking You For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer ACS No. A25784 Annexure-A Sl. No. Particulars Details 1. Name of the party Bengaluru North City Corporation (BNCC) or Greater Bengaluru Authority (‘GBA’) (successor to Bruhat Bengaluru Mahanagara Palike) 2. Details of change in the status Pursuant to dismissal of a Writ Appeal filed and / or any development in before the Hon’ble High Court of Karnataka, a relation to the proceedings demand notice is anticipated to be issued by BNCC / GBA, which is likely to be the improvement charges and applicable interest under the provisions of Greater Bengaluru Governance Act, 2024 read with Karnataka Municipal Corporations Act, 1976. 3. Compensation/ Penalty paid, if Nil. The Company will examine the demand any and the underlying computation and based on the outcome of such examination, will take appropriate action. 4. Expected financial implications The quantifiable monetary impact will be limited to the amount ascertained by BNCC / GBA to be finally levied on the Company under a revised anticipated demand notice. The likely improvement charges should not exceed INR 70.8 million and in addition there is likely to be applicable interest as computed by the BNCC / GBA. The Company has presently made an additional provision of INR 156.1 million in its books of accounts, based on the estimates.